AU784226B2 - Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix - Google Patents
Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix Download PDFInfo
- Publication number
- AU784226B2 AU784226B2 AU29255/01A AU2925501A AU784226B2 AU 784226 B2 AU784226 B2 AU 784226B2 AU 29255/01 A AU29255/01 A AU 29255/01A AU 2925501 A AU2925501 A AU 2925501A AU 784226 B2 AU784226 B2 AU 784226B2
- Authority
- AU
- Australia
- Prior art keywords
- peptide
- release
- polymer
- poly
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17413799P | 1999-12-31 | 1999-12-31 | |
US60/174137 | 1999-12-31 | ||
PCT/US2001/000030 WO2001049249A2 (fr) | 1999-12-31 | 2001-01-02 | Formulation pharmaceutique destinee a reguler la liberation dans le temps de composes biologiquement actifs a base d'une matrice polymere |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2925501A AU2925501A (en) | 2001-07-16 |
AU784226B2 true AU784226B2 (en) | 2006-02-23 |
Family
ID=22634986
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU29255/01A Expired AU784226B2 (en) | 1999-12-31 | 2001-01-02 | Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1263453A4 (fr) |
JP (1) | JP2003519164A (fr) |
AU (1) | AU784226B2 (fr) |
CA (1) | CA2396037A1 (fr) |
WO (1) | WO2001049249A2 (fr) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2395892C (fr) | 1999-12-31 | 2014-06-03 | Rutgers, The State University | Formulation pharmaceutique composee d'un melange polymere et d'un compose actif pour une liberation regulee dans le temps |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
JP5105578B2 (ja) | 2003-11-05 | 2012-12-26 | サーコード バイオサイエンス インコーポレイテッド | 細胞接着のモジュレーター |
CA2960117C (fr) | 2005-05-17 | 2018-01-30 | Sarcode Bioscience Inc. | Antagonistes de lfa-1 destines au traitement de troubles de l'oeil |
EP2114298B1 (fr) | 2006-02-08 | 2022-10-19 | Medtronic, Inc. | Prothèses de type treillis temporairement raidies |
US8315700B2 (en) | 2006-02-08 | 2012-11-20 | Tyrx, Inc. | Preventing biofilm formation on implantable medical devices |
US9265865B2 (en) | 2006-06-30 | 2016-02-23 | Boston Scientific Scimed, Inc. | Stent having time-release indicator |
CA2667873A1 (fr) | 2006-11-06 | 2008-10-23 | Tyrx Pharma, Inc. | Pochettes a mailles pour dispositifs medicaux implantables |
US9023114B2 (en) | 2006-11-06 | 2015-05-05 | Tyrx, Inc. | Resorbable pouches for implantable medical devices |
CA2682190C (fr) | 2007-03-29 | 2015-01-27 | Tyrx Pharma, Inc. | Enveloppes polymeres biodegradables pour implants mammaires |
CA2853772C (fr) | 2007-05-02 | 2016-08-09 | Tyrx, Inc. | Polymeres de dihydroxybenzoate et leurs utilisations |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
DK2170930T3 (da) | 2007-06-04 | 2012-11-05 | Synergy Pharmaceuticals Inc | Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme |
WO2009054914A1 (fr) | 2007-10-19 | 2009-04-30 | Sarcode Corporation | Compositions et procédés pour le traitement de la rétinopathie diabétique |
WO2009139817A2 (fr) | 2008-04-15 | 2009-11-19 | Sarcode Corporation | Produit pharmaceutique cristallin et ses procédés de préparation et d'utilisation |
JP2011522828A (ja) | 2008-06-04 | 2011-08-04 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
WO2010006046A1 (fr) | 2008-07-10 | 2010-01-14 | Tyrx Pharma, Inc. | Administration de médicaments anti-inflammatoires non stéroïdiens issus de polyarylates |
ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
WO2010033995A1 (fr) | 2008-09-22 | 2010-03-25 | Tyrx Pharma, Inc. | Polyesteramides linéaires d'esters aminophénoliques |
US9839628B2 (en) | 2009-06-01 | 2017-12-12 | Tyrx, Inc. | Compositions and methods for preventing sternal wound infections |
JP5847706B2 (ja) * | 2009-06-01 | 2016-01-27 | タイレックス・インコーポレイテッドTyrx Inc. | 胸骨創感染症を予防するための組成物および方法 |
WO2011014860A1 (fr) * | 2009-07-31 | 2011-02-03 | Rutgers, The State University Of New Jersey | Monomères et compositions de polymères biocompatibles à phases séparées préparées à partir de ceux-ci pour des utilisations médicales |
US8409279B2 (en) | 2009-10-01 | 2013-04-02 | Lipose Corporation | Breast implant implantation method and apparatus |
US8378105B2 (en) | 2009-10-21 | 2013-02-19 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
JP6031033B2 (ja) | 2010-08-25 | 2016-11-24 | タイレックス・インコーポレイテッドTyrx Inc. | 医療デバイスの新規なコーティング |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
JP6397190B2 (ja) | 2010-11-12 | 2018-09-26 | タイレックス・インコーポレイテッドTyrx Inc. | 有効医薬品成分を含む固着装置 |
EP2734248B1 (fr) | 2011-07-20 | 2018-10-17 | Tyrx, Inc. | Grille d'élution de médicament destiné à prévenir une infection des dispositifs transcutanés résidents |
CA2879982C (fr) | 2012-07-25 | 2020-09-01 | Sarcode Bioscience Inc. | Inhibiteur de lfa-1 et polymorphe de celui-ci |
EP2958577A2 (fr) | 2013-02-25 | 2015-12-30 | Synergy Pharmaceuticals Inc. | Agonistes du recepteur de la guanylate cyclase pour l'utilisation dans l'irrigation du colon |
WO2014137454A1 (fr) | 2013-03-07 | 2014-09-12 | Tyrx, Inc. | Procédés et compositions permettant d'inhiber l'assemblage de cellules microbiennes se liant de façon irréversible à la surface de dispositifs médicaux |
US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
JP6661531B2 (ja) | 2013-10-10 | 2020-03-11 | シナジー ファーマシューティカルズ インコーポレイテッド | オピオイド誘発性機能障害の治療に有用なグアニル酸シクラーゼのアゴニスト |
EP3065788A1 (fr) | 2013-11-08 | 2016-09-14 | Tyrx, Inc. | Compositions antimicrobiennes et procédés de prévention d'infection dans des sites d'incision chirurgicale |
WO2016020308A1 (fr) * | 2014-08-04 | 2016-02-11 | Janssen Sciences Ireland Uc | Forme posologique solide comprimée |
EP3402804A1 (fr) | 2016-01-11 | 2018-11-21 | Synergy Pharmaceuticals Inc. | Formulations et méthodes pour traiter la rectocolite hémorragique |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5587507A (en) * | 1995-03-31 | 1996-12-24 | Rutgers, The State University | Synthesis of tyrosine derived diphenol monomers |
US5658995A (en) * | 1995-11-27 | 1997-08-19 | Rutgers, The State University | Copolymers of tyrosine-based polycarbonate and poly(alkylene oxide) |
US6120491A (en) * | 1997-11-07 | 2000-09-19 | The State University Rutgers | Biodegradable, anionic polymers derived from the amino acid L-tyrosine |
US6284862B1 (en) * | 1997-02-18 | 2001-09-04 | Rutgers, The State University | Monomers derived from hydroxy acids and polymers prepared therefrom |
DE19719817A1 (de) * | 1997-05-13 | 1998-11-19 | Hoechst Ag | Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren |
AU1819499A (en) * | 1997-12-12 | 1999-06-28 | Samyang Corporation | Positively-charged poly{alpha-(omega-aminoalkyl)glycolic acid} for the delivery of a bioactive agent via tissue and cellular uptake |
JP4312384B2 (ja) * | 1998-04-13 | 2009-08-12 | ラットガーズ ザ ステイト ユニヴァーシティ | コポリマーライブラリーの構築 |
AU2373200A (en) * | 1999-02-05 | 2000-08-25 | Alien Technology Corporation | Apparatuses and methods for forming assemblies |
-
2001
- 2001-01-02 CA CA002396037A patent/CA2396037A1/fr not_active Abandoned
- 2001-01-02 AU AU29255/01A patent/AU784226B2/en not_active Expired
- 2001-01-02 JP JP2001549618A patent/JP2003519164A/ja active Pending
- 2001-01-02 EP EP01939971A patent/EP1263453A4/fr not_active Ceased
- 2001-01-02 WO PCT/US2001/000030 patent/WO2001049249A2/fr active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2001049249A2 (fr) | 2001-07-12 |
AU2925501A (en) | 2001-07-16 |
WO2001049249A3 (fr) | 2002-01-17 |
CA2396037A1 (fr) | 2001-07-12 |
EP1263453A4 (fr) | 2008-02-20 |
EP1263453A2 (fr) | 2002-12-11 |
JP2003519164A (ja) | 2003-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU784226B2 (en) | Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix | |
US7521061B2 (en) | Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix | |
AU775905B2 (en) | Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release | |
AU600723B2 (en) | Biodegradable microspheres as a carrier for macromolecules | |
Chiu et al. | Synthesis and characterization of pH-sensitive dextran hydrogels as a potential colon-specific drug delivery system | |
Tabata et al. | Controlled delivery systems for proteins using polyanhydride microspheres | |
Ulbrich et al. | Synthesis of novel hydrolytically degradable hydrogels for controlled drug release | |
ES2212037T3 (es) | Copolimeros de polieterester como matrices para la administracion de medicamentos. | |
Ranade | Drug delivery systems: 3A. Role of polymers in drug delivery | |
Tatykhanova et al. | Ophthalmic drug delivery system based on the complex of gellan and ofloxacin | |
Gwon et al. | New route for synthesizing poly (ethylene glycol)-acrylic acid hydrogels using γ-irradiation for drug delivery carriers | |
Gautier et al. | Poly (L-Lysine Citramide), a water-soluble bioresorbable carrier for drug delivery: Aqueous solution properties of hydrophobized derivatives | |
WO2014102741A2 (fr) | Forme posologique pharmaceutique | |
Sparer | Controlled release of drugs from glycosaminoglycan drug complexes | |
CN1476325B (zh) | 活性物质的输送系统和活性物质的保护和施用方法 | |
US8709481B2 (en) | System for controlled release of an active principle and method for preparation | |
CA1297627C (fr) | Polymeres biodegradables pour les preparations de depot a liberation lente ducompose actif | |
Ye et al. | The properties of polyesteramide and the effects on the stability of bovine serum albumin | |
Jeong et al. | Hydrogels for oral administration | |
Rypáček et al. | Self-Degradable Hydrogel with Covalently Bound Proteolytic Enzyme | |
Park et al. | Hydrogels for Drug Delivery System:-Colon-Specific Delivery | |
Singh | Smart polymer-based controlled-release drug-delivery systems for peptide and protein | |
Markland | Modified polypeptides and polypeptide hydrogels for controlled drug delivery | |
WO2004017937A1 (fr) | Composition biodegradable a liberation prolongee de principes bioactifs et mode de preparation | |
WO2008152669A2 (fr) | Vecteurs colloïdaux à structure polyaminoacide pour une libération orale de peptides et de protéines et leur méthode de production |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |